Methamphetamine Use Disorder: Risks, Withdrawal, and Treatment
Plain, fact-first answers about how care works here. Want to talk to a person? Call (888) 464-2144.
- The Archangel Centers is a licensed outpatient addiction treatment provider.
- The Archangel Centers operates clinics in Tinton Falls, NJ and Charlotte, NC.
- Methamphetamine use disorder is part of the outpatient continuum at The Archangel Centers.
- Medication-assisted treatment (MAT) includes Suboxone, Vivitrol, and Sublocade.
- The Archangel Centers works with most major commercial insurance plans with free benefits verification.
Methamphetamine is a potent synthetic stimulant with a long history of medical use (for ADHD, narcolepsy, and obesity in tightly controlled formulations) and a much larger history of illicit use. The current illicit supply is dominated by high-purity, low-cost methamphetamine produced largely outside the United States. Use disorders have risen sharply in the past decade, often in patterns of overlap with opioid use, and meth-involved overdose deaths now include a meaningful share involving fentanyl contamination. This page covers methamphetamine pharmacology, the specific medical and psychiatric risks, the withdrawal pattern, and evidence-based treatment.
There are currently no FDA-approved medications specifically for methamphetamine use disorder. Treatment evidence concentrates on structured behavioral approaches and treatment of co-occurring conditions.
What methamphetamine is
Methamphetamine is a sympathomimetic stimulant chemically related to amphetamine but more potent and longer-acting. It releases dopamine, norepinephrine, and serotonin into the synapse and blocks their reuptake, producing prolonged stimulant effect. The illicit form is most commonly the smokable or injectable "crystal meth" (d-methamphetamine hydrochloride).
Routes of use include smoking (most common in current U.S. patterns), injection, snorting, and oral use. Effects last 6 to 12 hours, much longer than cocaine, which drives a different binge pattern.
The current supply context
Two facts shape the current clinical picture:
1. High purity, low cost. The illicit supply over the past decade has shifted from small-scale domestic production to large-scale production by international networks, with much higher potency at much lower prices than historical street meth. 2. Fentanyl contamination is real. Although less prevalent than in heroin, fentanyl contamination of methamphetamine has been documented in many U.S. markets. Carry naloxone.
These shifts are why the medical profile of meth use disorder today is more severe than it was twenty years ago.
Health risks
Cardiovascular
- Hypertension
- Tachycardia, arrhythmias
- Stroke (both ischemic and hemorrhagic)
- Methamphetamine-associated cardiomyopathy (weakened heart muscle), increasingly recognized as a major cause of heart failure in younger adults
- Pulmonary hypertension
Neurological
- Stroke
- Seizures
- Long-term cognitive impairment (memory, executive function), with evidence of partial recovery in sustained abstinence
- Movement disorders in chronic users
Psychiatric
- Methamphetamine-induced psychosis: paranoia, hallucinations, delusions, agitation; can persist for days to weeks
- Severe depression in withdrawal, with suicidality risk
- Worsening of underlying mood, anxiety, and trauma conditions
- Aggression and violence during acute use, often associated with sleep deprivation
Other
- Severe dental disease ("meth mouth")
- Skin lesions from picking
- Significant weight loss and malnutrition
- HIV and hepatitis C from injection or shared paraphernalia
- Sexual risk behaviors during use, particularly in men who have sex with men contexts where chemsex is involved
What does methamphetamine withdrawal look like?
Methamphetamine withdrawal is primarily psychological, but the depression and exhaustion can be severe. The typical pattern:
Suicidality in the post-crash window is a real clinical concern. Treatment in this phase often includes close monitoring and (where indicated) inpatient stabilization. The Archangel Centers does not provide inpatient or detox on-site; we coordinate placement with accredited partner facilities when needed.
- Crash phase (within 24 hours of stopping): exhaustion, deep sleep, increased appetite, low mood
- Withdrawal phase (days 2 to 10): depression, anhedonia, cognitive sluggishness, intense craving, vivid dreams, irritability
- Extinction phase (weeks to months): intermittent craving, gradual mood improvement, cognitive recovery
Methamphetamine use disorder, formally
Diagnosis follows the DSM-5 substance use disorder framework applied to amphetamine-type stimulants, with at least two of eleven criteria within twelve months. Common patterns:
- Daily smoking that has escalated to multiple uses per day, often with sleep deprivation
- Binge patterns lasting days at a time, followed by crash and recovery, then repeat
- Use combined with sexual activity (chemsex contexts)
- Use combined with opioids, either intentionally or via contaminated supply
How is methamphetamine use disorder treated?
No FDA-approved medications exist for methamphetamine use disorder. Treatment concentrates in the following.
Which behavioral therapies have the strongest evidence?
- Contingency management Structured reinforcement for verified abstinence. The strongest evidence base of any behavioral intervention for stimulant use disorder.
- The Matrix Model A manualized outpatient program for stimulant use disorder, combining CBT, family education, 12-step support, and individual counseling.
- Cognitive behavioral therapy See CBT.
- Motivational interviewing See motivational interviewing.
- Mindfulness-based relapse prevention.
How are co-occurring conditions treated?
Methamphetamine use disorder is heavily comorbid with depression, ADHD, anxiety, and trauma-related disorders. Treating the underlying conditions reduces use. See depression and addiction, ADHD and addiction, and PTSD and addiction.
Off-label and emerging pharmacotherapy
Several medications have shown signal in trials for stimulant use disorder, though none are currently FDA-approved for this indication. Clinical decisions about off-label use are made by the medical provider on a case-by-case basis.
What is the outpatient continuum?
For clients in active psychosis or with severe medical complications, coordinated inpatient placement is often the right starting point.
- PHP at Tinton Falls or PHP at Charlotte for the post-crash phase, when structured environment is most useful
- IOP at Tinton Falls or IOP at Charlotte as the post-PHP step-down
- OP for ongoing care
Co-occurring opioid use
Polysubstance use of methamphetamine and opioids is increasingly common. When both are present, the treatment plan addresses both, with MAT for the opioid component (Suboxone, Sublocade, or Vivitrol; methadone is not in our formulary). See polysubstance use.
Frequently Asked Questions
Does the brain recover after long-term meth use?
Is meth-induced psychosis permanent?
Can I do outpatient treatment for meth?
What about prescription stimulants for ADHD?
Will my insurance cover treatment?
Is meth treatment effective?
What if I am still in active psychosis or severely paranoid when I call?
How does The Archangel Centers handle methamphetamine treatment when opioids are also involved?
Related Pages
Admissions are confidential and staffed 24/7 at (888) 464-2144. Or browse a specific clinic page for hours, address, and the full program.